不良临床事件报告

J. Dill, T. Mcevoy
{"title":"不良临床事件报告","authors":"J. Dill, T. Mcevoy","doi":"10.1177/00694770211051270","DOIUrl":null,"url":null,"abstract":"A 70-year-old male patient developed worsening pain and swelling of the left breast of 1 month duration. Medications at the time of medical evaluation included bicalutamide (50 mg daily for 12 months), atorvastatin (20 mg daily), allopurinol, acetylsalicylic acid, and tamsulosin. No vitamins or herbal supplements were noted on the medication history. A physical examination revealed a tender enlarged left breast without bleeding or discharge. Imaging studies indicated an enlarged left breast with normal glandular tissues and vascularity. Laboratory values were within normal limits. Treatment included the substitution of ezetimibe (10 mg daily) for atorvastatin, resulting in symptomatic improvement by 3 months without recurrence. The authors concluded that this patient developed atorvastatin-related gynecomastia based on the temporal relationship between the administration of the drug and the appearance and resolution of symptoms. According to the Naranjo causality scale, this relationship between the drug and causality was classified as probable. Atorvastatin [Atorvastatin] Famularo G et al (Giuseppe Famularo: San Camillo Hospital, Rome, Italy; e-mail: None provided) Atorvastatin-associated gynecomastia. Ann Pharmacotherapy 55(10):1300–1301 (Oct) 2021","PeriodicalId":102871,"journal":{"name":"Clin-Alert®","volume":"13 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Reporting on Adverse Clinical Events\",\"authors\":\"J. Dill, T. Mcevoy\",\"doi\":\"10.1177/00694770211051270\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A 70-year-old male patient developed worsening pain and swelling of the left breast of 1 month duration. Medications at the time of medical evaluation included bicalutamide (50 mg daily for 12 months), atorvastatin (20 mg daily), allopurinol, acetylsalicylic acid, and tamsulosin. No vitamins or herbal supplements were noted on the medication history. A physical examination revealed a tender enlarged left breast without bleeding or discharge. Imaging studies indicated an enlarged left breast with normal glandular tissues and vascularity. Laboratory values were within normal limits. Treatment included the substitution of ezetimibe (10 mg daily) for atorvastatin, resulting in symptomatic improvement by 3 months without recurrence. The authors concluded that this patient developed atorvastatin-related gynecomastia based on the temporal relationship between the administration of the drug and the appearance and resolution of symptoms. According to the Naranjo causality scale, this relationship between the drug and causality was classified as probable. Atorvastatin [Atorvastatin] Famularo G et al (Giuseppe Famularo: San Camillo Hospital, Rome, Italy; e-mail: None provided) Atorvastatin-associated gynecomastia. Ann Pharmacotherapy 55(10):1300–1301 (Oct) 2021\",\"PeriodicalId\":102871,\"journal\":{\"name\":\"Clin-Alert®\",\"volume\":\"13 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clin-Alert®\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/00694770211051270\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clin-Alert®","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/00694770211051270","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

患者男性,70岁,左乳疼痛肿胀加重,持续1个月。医学评估时的药物包括比卡鲁胺(每天50毫克,持续12个月)、阿托伐他汀(每天20毫克)、别嘌呤醇、乙酰水杨酸和坦索罗辛。用药史上没有维生素或草药补充剂。体格检查发现左侧乳房肿大,无出血或分泌物。影像学检查显示左乳房肿大,腺体组织和血管正常。实验室值在正常范围内。治疗包括以依折替贝(每日10mg)替代阿托伐他汀,导致症状改善3个月无复发。作者得出结论,该患者发展为阿托伐他汀相关的男性乳房发育基于给药与症状的出现和消退之间的时间关系。根据纳兰霍因果关系量表,药物和因果关系之间的这种关系被归类为可能。阿托伐他汀[阿托伐他汀]Famularo等人(Giuseppe Famularo:圣卡米洛医院,罗马,意大利;电子邮件:无提供)阿托伐他汀相关的男性乳房发育症。Ann药物治疗55(10):1300-1301 (Oct) 2021
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Reporting on Adverse Clinical Events
A 70-year-old male patient developed worsening pain and swelling of the left breast of 1 month duration. Medications at the time of medical evaluation included bicalutamide (50 mg daily for 12 months), atorvastatin (20 mg daily), allopurinol, acetylsalicylic acid, and tamsulosin. No vitamins or herbal supplements were noted on the medication history. A physical examination revealed a tender enlarged left breast without bleeding or discharge. Imaging studies indicated an enlarged left breast with normal glandular tissues and vascularity. Laboratory values were within normal limits. Treatment included the substitution of ezetimibe (10 mg daily) for atorvastatin, resulting in symptomatic improvement by 3 months without recurrence. The authors concluded that this patient developed atorvastatin-related gynecomastia based on the temporal relationship between the administration of the drug and the appearance and resolution of symptoms. According to the Naranjo causality scale, this relationship between the drug and causality was classified as probable. Atorvastatin [Atorvastatin] Famularo G et al (Giuseppe Famularo: San Camillo Hospital, Rome, Italy; e-mail: None provided) Atorvastatin-associated gynecomastia. Ann Pharmacotherapy 55(10):1300–1301 (Oct) 2021
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信